Seminars in Nephrology
Volume 29, Issue 3 , Pages 175-177 , May 2009

Hyponatremia: Introduction

References 

  1. Ciura S, Bourque CW. Transient receptor potential vanilloid 1 is required for intrinsic osmoreception in organum vasculosum lamina terminalis neurons and for normal thirst responses to systemic hyperosmolality. J Neurosci. 2006;26:9069–9075
  2. Sharif Naeini R, Witty MF, Seguela P, Bourque CW. An N-terminal variant of Trpv1 channel is required for osmosensory transduction. Nat Neurosci. 2006;9:93–98
  3. Liedtke W, Friedman JM. Abnormal osmotic regulation in trpv4-/- mice. Proc Natl Acad Sci U S A. 2003;100:13698–13703
  4. Mizuno A, Matsumoto N, Imai M, Suzuki M. Impaired osmotic sensation in mice lacking TRPV4. Am J Physiol Cell Physiol. 2003;285:C96–C101
  5. Fenton RA, Chou CL, Stewart GS, Smith CP, Knepper MA. Urinary concentrating defect in mice with selective deletion of phloretin-sensitive urea transporters in the renal collecting duct. Proc Natl Acad Sci U S A. 2004;101:7469–7474
  6. Robertson GL. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am J Med. 2006;119(Suppl 1):S36–S42
  7. Sasaki S. Is oxytocin a player in antidiuresis?. J Am Soc Nephrol. 2008;19:189–190
  8. Feldman BJ, Rosenthal SM, Vargas GA, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med. 2005;352:1884–1890
  9. Soule S, Florkowski C, Potter H, et al. Intermittent severe, symptomatic hyponatraemia due to the nephrogenic syndrome of inappropriate antidiuresis. Ann Clin Biochem. 2008;45:520–523
  10. Marcialis MA, Faa V, Fanos V, et al. Neonatal onset of nephrogenic syndrome of inappropriate antidiuresis. Pediatr Nephrol. 2008;23:2267–2271
  11. Decaux G, Vandergheynst F, Bouko Y, et al. Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol. 2007;18:606–612
  12. Tanaka Y, Sugita K, Saito T, et al. Impaired urinary water excretion in a three-generation family. Pediatr Nephrol. 2001;16:820–822
  13. Ayus JC, Arieff AI. Pulmonary complications of hyponatremic encephalopathy (Noncardiogenic pulmonary edema and hypercapnic respiratory failure). Chest. 1995;107:517–521
  14. Ayus JC, Varon J, Arieff AI. Hyponatremia, cerebral edema, and noncardiogenic pulmonary edema in marathon runners. Ann Intern Med. 2000;132:711–714
  15. Ellison DH, Berl T. Clinical practice (The syndrome of inappropriate antidiuresis). N Engl J Med. 2007;356:2064–2072
  16. Sugimura Y, Murase T, Takefuji S, et al. Protective effect of dexamethasone on osmotic-induced demyelination in rats. Exp Neurol. 2005;192:178–183
  17. Baker EA, Tian Y, Adler S, Verbalis JG. Blood-brain barrier disruption and complement activation in the brain following rapid correction of chronic hyponatremia. Exp Neurol. 2000;165:221–230
  18. Adler S, Verbalis JG, Meyers S, Simplaceanu E, Williams DS. Changes in cerebral blood flow and distribution associated with acute increases in plasma sodium and osmolality of chronic hyponatremic rats. Exp Neurol. 2000;163:63–71
  19. Adler S, Martinez J, Williams DS, Verbalis JG. Positive association between blood brain barrier disruption and osmotically-induced demyelination. Mult Scler. 2000;6:24–31
  20. Qi X, Inagaki K, Sobel RA, Mochly-Rosen D. Sustained pharmacological inhibition of deltaPKC protects against hypertensive encephalopathy through prevention of blood-brain barrier breakdown in rats. J Clin Invest. 2008;118:173–182
  21. Ayus JC, Arieff AI. Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. JAMA. 1999;281:2299–2304
  22. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006;119:e71–e78
  23. Gankam Kengne F, Andres C, Sattar L, Melot C, Decaux G. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM. 2008;101:583–588
  24. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27:447–457
  25. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112
  26. Mohmand HK, Issa D, Ahmad Z, et al. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin J Am Soc Nephrol. 2007;2:1110–1117
  27. Perianayagam A, Sterns RH, Silver SM, et al. DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia. Clin J Am Soc Nephrol. 2008;3:331–336

 Dr Mount has been a member of the speaker's bureau for Astellas, the makers of conivaptan.

PII: S0270-9295(09)00023-0

doi: 10.1016/j.semnephrol.2009.03.007

Seminars in Nephrology
Volume 29, Issue 3 , Pages 175-177 , May 2009

Article Tools